News from merrimack pharmaceuticals, inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Aug 10, 2015, 16:01 ET

Merrimack Pharmaceuticals Reports Second Quarter 2015 Financial Results

Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK), a biopharmaceutical company discovering, developing and preparing to commercialize innovative...

Aug 06, 2015, 08:00 ET

Merrimack Pharmaceuticals Names Dr. Yasir Al-Wakeel as Chief Financial Officer and Head of Corporate Development

 Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced that Yasir Al-Wakeel, MA, BM BCh will be appointed Chief Financial Officer and...

Aug 03, 2015, 08:00 ET

Merrimack Pharmaceuticals Announces Timing of Second Quarter 2015 Investor Conference Call

Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced that the company will host its Second Quarter 2015 Investor Conference Call and...

Jun 25, 2015, 07:00 ET

U.S. FDA Grants Priority Review for MM-398 New Drug Application

 Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) and Baxalta Incorporated, a wholly-owned subsidiary of Baxter International Inc (NYSE: BAX),...

Jun 15, 2015, 16:01 ET
John M. Dineen

Merrimack Pharmaceuticals Announces the Addition of John M. Dineen, Former CEO of GE Healthcare, to Its Board of Directors

Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced the election of John M. Dineen to its Board of Directors. Dineen, the...

Jun 11, 2015, 17:00 ET

Merrimack Pharmaceuticals Announces Expansion of MM-398 (nal-IRI) Imaging Study to Patients with Metastatic Breast Cancer

 Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced the initiation of clinical imaging assessing the use of a potential marker...

Jun 01, 2015, 16:12 ET

Merrimack Pharmaceuticals Announces Data from an Investigator-Sponsored Phase 1 Study Showing Acceptable Safety Profile for MM-398 in High-Grade Glioma

 Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced data for MM-398 (irinotecan liposome injection), also known as...

May 14, 2015, 08:00 ET

Merrimack Pharmaceuticals Announces Presentations at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting

Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced that data supporting further research and clinical development of MM-398 will...

May 07, 2015, 16:01 ET

Merrimack Pharmaceuticals Reports First Quarter 2015 Financial Results

Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK), a biopharmaceutical company discovering, developing and preparing to commercialize innovative...

May 05, 2015, 08:00 ET

Merrimack Pharmaceuticals Announces Initiation of a Phase 2 Front-line Clinical Trial of MM-141 in Biomarker-Selected Patients with Metastatic Pancreatic Cancer

Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced the initiation of a randomized, double-blinded, placebo-controlled Phase 2...

Apr 28, 2015, 16:15 ET

Merrimack Pharmaceuticals Announces Timing of First Quarter 2015 Investor Conference Call and Presentation at Credit Suisse 2015 Antibody Conference

Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced that the company will hold its First Quarter 2015 Investor Conference Call and...

Apr 27, 2015, 07:00 ET

Merrimack Pharmaceuticals and Baxter BioScience Announce Completion of New Drug Application Submission to U.S. FDA for MM-398 as a Treatment for Post-Gemcitabine Metastatic Pancreatic Cancer

Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) and Baxter International Inc. (NYSE: BAX) today jointly announced that Merrimack has completed the...

Apr 21, 2015, 08:00 ET

First-in-Human Phase 1 Trial of MM-141 Demonstrates Activity in Biomarker Positive Patients

Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced updated clinical data from a multi-arm Phase 1 study of MM-141, a bispecific...

Apr 20, 2015, 16:01 ET

Merrimack Announces Final Clinical Results for MM-302 Phase 1 Study Demonstrating Robust Activity in Heavily Pre-Treated Patients with HER2-Positive Metastatic Breast Cancer

Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) announced updated and final clinical results for the Phase 1 study of MM-302, a novel HER2-targeted...

Mar 26, 2015, 08:00 ET

Merrimack to Highlight Extensive Oncology Pipeline at the 2015 American Association for Cancer Research Annual Meeting

 Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced that it will present preclinical and clinical data showcasing its deep...

Oct 30, 2013, 06:00 ET

Merrimack Pharmaceuticals Announces Results From A Phase 2 Study Of MM-121 (SAR256212) In Combination With Paclitaxel In Patients With Platinum-Resistant Or Refractory Advanced Ovarian Cancers

 Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) today announced results of a global, Phase 2, open-label, randomized study of MM-121 in...

Jun 04, 2013, 09:00 ET

Merrimack Pharmaceuticals' Phase 1 Research Supports MM-121 Potential For Investigation As Combination With Chemotherapy In Patients With Advanced Solid Tumors

Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) today announced results from a Phase 1 clinical study that indicate the novel antibody MM-121 can be...

Apr 10, 2013, 09:00 ET

Merrimack Pharmaceuticals' Preclinical Research Shows MM-111 Restores Sensitivity To Chemotherapy And HER2-targeted Treatment In Gastric Cancer Model

 Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) today announced preclinical study results showing that the novel bispecific therapy MM-111...

Apr 08, 2013, 08:00 ET

Merrimack Pharmaceuticals' Preclinical Research Shows MM-121 Restores Sensitivity to Anti-Estrogen Therapy and Delays Onset of Treatment Resistance in ER-Positive Breast Cancer Model

Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) today announced preclinical study results showing that the novel therapy MM-121 restores tumor...

Apr 04, 2013, 08:00 ET

Merrimack Pharmaceuticals Announces Top-Line Results From A Single Arm Phase 2 Advanced Lung Cancer Study In Patients With Resistance To An Anti-EGFR Tyrosine Kinase Inhibitor

Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) today announced that one cohort of a Phase 2 non-small cell lung cancer (NSCLC) study did not meet...